enGene Ownership | Who Owns enGene?
enGene Ownership Summary
enGene is owned by 82.96% institutional investors, 0.09% insiders, and 16.95% retail investors. Fcpm iii services b.v. is the largest institutional shareholder, holding 14.32% of ENGN shares. Polar Capital Biotech S Inc is the top mutual fund, with 1.73% of its assets in enGene shares.
ENGN Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | enGene | 82.96% | 0.09% | 16.95% |
| Sector | Healthcare Stocks | 35.58% | 11.87% | 52.55% |
| Industry | Biotech Stocks | 35.75% | 11.83% | 52.41% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Fcpm iii services b.v. | 9.63M | 14.32% | $65.60M |
| Perceptive advisors | 5.83M | 8.66% | $39.69M |
| Siren | 5.25M | 7.81% | $35.77M |
| Vr adviser | 4.77M | 7.09% | $32.49M |
| Blue owl capital lp | 4.42M | 6.57% | $30.08M |
| Deep track capital, lp | 4.38M | 6.51% | $29.81M |
| Braidwell lp | 2.46M | 3.65% | $16.73M |
| Nextech invest | 2.32M | 3.46% | $15.83M |
| Vestal point capital, lp | 2.17M | 3.22% | $14.74M |
| Bioimpact capital | 1.85M | 2.74% | $12.57M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Fcpm iii services b.v. | 9.63M | 9.08% | $65.60M |
| Blue owl capital lp | 4.42M | 8.08% | $30.08M |
| Omega fund management | 876.36K | 3.66% | $5.97M |
| Vr adviser | 4.77M | 1.21% | $32.49M |
| Monashee investment management | 320.00K | 1.19% | $2.18M |
| Nextech invest | 2.32M | 1.11% | $15.83M |
| Siren | 5.25M | 0.99% | $35.77M |
| Bioimpact capital | 1.85M | 0.97% | $12.57M |
| Birchview capital, lp | 250.00K | 0.97% | $1.70M |
| Perceptive advisors | 5.83M | 0.78% | $39.69M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Siren | 5.25M | 0.99% | 1.92M |
| Balyasny asset management | 1.15M | 0.01% | 1.15M |
| Vestal point capital, lp | 2.17M | 0.41% | 1.11M |
| Blue owl capital lp | 4.42M | 8.08% | 1.06M |
| Kennedy capital management | 425.78K | 0.06% | 349.02K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Cormorant asset management, lp | - | - | -4.00M |
| Janus henderson group | - | - | -1.90M |
| Frazier life sciences management | - | - | -1.16M |
| Eventide asset management | - | - | -950.00K |
| Orbimed advisors | - | - | -677.98K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Balyasny asset management | 1.15M | 0.01% | 1.15M | $7.82M |
| Birchview capital, lp | 250.00K | 0.97% | 250.00K | $1.70M |
| Fmr | 232.20K | 0.00% | 232.20K | $1.58M |
| Trexquant investment lp | 104.70K | 0.01% | 104.70K | $712.99K |
| Sei investments | 60.04K | 0.00% | 60.04K | $408.85K |
Sold Out
| Holder | Change |
|---|---|
| Sbi securities | -28.00 |
| Nbc securities | -380.00 |
| Mai capital management | -776.00 |
| Wolverine asset management | -6.36K |
| Paloma partners management | -10.32K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 59 | 3.51% | 55,801,630 | -4.94% | 82 | 0.63% | 34 | -20.93% | 14 | 75.00% |
| Dec 31, 2025 | 27 | -28.95% | 17,021,462 | -58.35% | 33 | 0.52% | 21 | 50.00% | 2 | -75.00% |
| Sep 30, 2025 | 38 | 2.70% | 40,868,497 | 1.11% | 79 | 1.27% | 14 | 7.69% | 8 | -11.11% |
| Jun 30, 2025 | 37 | 19.35% | 40,420,485 | -1.27% | 79 | 1.23% | 13 | 44.44% | 9 | 12.50% |
| Mar 31, 2025 | 31 | -8.82% | 40,941,351 | -0.88% | 80 | 1.22% | 9 | -59.09% | 8 | 14.29% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Polar Capital Biotech S Inc | 1.16M | 1.73% | - |
| Eventide Healthcare & Life Sciences I | 950.00K | 1.42% | 950.00K |
| Franklin Biotechnology Discv A(acc)USD | 828.41K | 1.24% | - |
| Franklin Biotechnology Discovery A | 486.58K | 0.73% | - |
| Kennedy Micro Cap | 305.43K | 0.46% | 250.67K |
| Fidelity Select Biotechnology | 232.20K | 0.35% | - |
| Kennedy Micro Cap Opportunities | 120.35K | 0.18% | 98.35K |
| Fidelity Nasdaq Composite Index | 38.80K | 0.06% | - |
| Virtus LifeSci Biotech Clinical Trls ETF | 32.63K | 0.05% | - |
| Pleiades Small Cap Equity A | 30.02K | 0.04% | 24.48K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Oct 30, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | - | Buy | $5.00M |
| Oct 07, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | - | Buy | $77.53K |
| Oct 04, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | - | Buy | $39.24K |
| Oct 03, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | - | Buy | $37.40K |
| Oct 08, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | - | Buy | $5.28K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q3 | - | - |
| 2025 Q2 | - | - |
| 2025 Q1 | - | - |
| 2024 Q4 | 7 | - |
| 2024 Q3 | 4 | - |
ENGN Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools